AUTHOR=Santiago Jose A. , Bottero Virginie , Potashkin Judith A. 

TITLE=Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program

JOURNAL=Frontiers in Aging Neuroscience

VOLUME=10

YEAR=2018

URL=https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2018.00157

DOI=10.3389/fnagi.2018.00157

ISSN=1663-4365

ABSTRACT=<p>There is a high misdiagnosis rate between Parkinson’s disease (PD) and atypical parkinsonian disorders (APD), such as progressive supranuclear palsy (PSP), the second most common parkinsonian syndrome. In our earlier studies, we identified and replicated RNA blood biomarkers in several independent cohorts, however, replication in a cohort that includes PSP patients has not yet been performed. To this end, we evaluated the diagnostic potential of nine previously identified RNA biomarkers using quantitative PCR assays in 138 blood samples at baseline from PD, PSP and healthy controls (HCs) nested in the PD Biomarkers Program. Linear discriminant analysis showed that <italic>COPZ1</italic> and <italic>PTPN1</italic> distinguished PD from PSP patients with 62.5% accuracy. Five biomarkers, <italic>PTPN1</italic>, <italic>COPZ1</italic>, <italic>FAXDC2</italic>, <italic>SLC14A1s</italic> and <italic>NAMPT</italic> were useful for distinguishing PSP from controls with 69% accuracy. Several biomarkers correlated with clinical features in PD patients. <italic>SLC14A1-s</italic> correlated with Unified Parkinson’s Disease Rating Scale total and part III scores. In addition, <italic>COPZ1</italic>, <italic>PTPN1</italic> and <italic>MLST8</italic>, correlated with Montreal Cognitive Assessment (MoCA). Interestingly, <italic>COPZ1</italic>, <italic>EFTUD2</italic> and <italic>PTPN1</italic> were downregulated in cognitively impaired (CI) compared to normal subjects. Linear discriminant analysis showed that age, <italic>PTPN1</italic>, <italic>COPZ1</italic>, <italic>FAXDC2</italic>, <italic>EFTUD2</italic> and <italic>MLST8</italic> distinguished CI from normal subjects with 65.9% accuracy. These results suggest that <italic>COPZ1</italic> and <italic>PTPN1</italic> are useful for distinguishing PD from PSP patients. In addition, the combination of <italic>PTPN1</italic>, <italic>COPZ1</italic>, <italic>FAXDC2</italic>, <italic>EFTUD2</italic> and <italic>MLST8</italic> is a useful signature for cognitive impairment. Evaluation of these biomarkers in a larger study will be a key to advancing these biomarkers into the clinic.</p>